GOG

Guild of Guardians Announces "Age of the Dread" Launch Event with Prizes Valued at US$1 Million

Retrieved on: 
torsdag, maj 9, 2024
Google Play, Leaderboard, App Store (iOS/iPadOS), RPG, GOG, Act One, Video game

SYDNEY, May 8, 2024 /PRNewswire/ -- Guild of Guardians, the highly anticipated mobile RPG set to revolutionize the gaming industry, is proud to announce the upcoming launch of its epic Act 1 event, "Age of the Dread." To celebrate the first phase of the game's global release, Guild of Guardians has partnered with Guardians Guild Limited to secure unprecedented prizes to the value of up to US$1 million in $GOG for players.

Key Points: 
  • To celebrate the first phase of the game's global release, Guild of Guardians has partnered with Guardians Guild Limited to secure unprecedented prizes to the value of up to US$1 million in $GOG for players.
  • "We're thrilled to kick off Age of the Dread and offer players over US$1 million equivalent in total prizes up for grabs," said Chris Clay, Game Director for Guild of Guardians.
  • In addition to the US$1 million worth of $GOG prizes, Guild of Guardians will also be awarding weekly rewards to Leaderboard participants.
  • For more information on Guild of Guardians and Age of the Dread, please visit: https://www.guildofguardians.com .

Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

Retrieved on: 
fredag, april 19, 2024
Cancer, Ovary, Safety, Vulva, Pembrolizumab, Research, Bevacizumab, Uterus, Roche, Patient, Endometrium, Trophoblast, ASA, HPV16, Cervical cancer, GOG, Pharmaceutical industry

The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche’s checkpoint inhibitor atezolizumab (Tecentriq®1) in patients with HPV16-positive, PD-L1-positive, recurrent, or metastatic cervical cancer.

Key Points: 
  • The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche’s checkpoint inhibitor atezolizumab (Tecentriq®1) in patients with HPV16-positive, PD-L1-positive, recurrent, or metastatic cervical cancer.
  • Step 1 of VB-C-04 is a two-arm Phase 2 trial evaluating the efficacy and safety of VB10.16 alone or in combination with atezolizumab in patients with recurrent or metastatic cervical cancer refractory to first-line treatment with pembrolizumab plus chemotherapy +/- bevacizumab.
  • Dr. Bradley Monk, Director of GOG, said, "Today marks an important step forward in our efforts to advance cancer treatment with the initiation of the Phase 2 trial of VB10.16 in second line HPV16-positive cervical cancer.
  • “Initiating the VB10.16 trial for HPV16-positive cervical cancer addressing a high unmet medical need, is a significant step in our clinical development strategy," said Klaus Edvardsen, Chief Development Officer of Nykode Therapeutics.

Global Gas Trade Continued Its Move to Competitive Gas on Gas Pricing, while the Global Wholesale Gas Price Levels Cooled Off Slightly in 2023

Retrieved on: 
tisdag, april 23, 2024
Pipeline, MMBTU, Conference, GOG, Growth, Post-Soviet states, BIM, IGU, OPE, International Gas Union, Renewable energy

AMSTERDAM, April 23, 2024 /PRNewswire/ -- Flame Conference - The International Gas Union (IGU) releases its 2024 Global Wholesale Gas Price Survey report, the 16th undertaken since 2005.

Key Points: 
  • AMSTERDAM, April 23, 2024 /PRNewswire/ -- Flame Conference - The International Gas Union (IGU) releases its 2024 Global Wholesale Gas Price Survey report, the 16th undertaken since 2005.
  • Demand rebound in China and further growth in spot LNG imported into Europe contributed to the rise.
  • Global wholesale prices continued to significantly vary across regions, with Europe still remaining highest priced.
  • The maturing and growing flexibility of a truly global gas market are welcome signs from this year's survey results.

Global Gas Trade Continued Its Move to Competitive Gas on Gas Pricing, while the Global Wholesale Gas Price Levels Cooled Off Slightly in 2023

Retrieved on: 
tisdag, april 23, 2024
Pipeline, MMBTU, Conference, GOG, Growth, Post-Soviet states, BIM, IGU, OPE, International Gas Union, Renewable energy

AMSTERDAM, April 23, 2024 /PRNewswire/ -- Flame Conference - The International Gas Union (IGU) releases its 2024 Global Wholesale Gas Price Survey report, the 16th undertaken since 2005.

Key Points: 
  • AMSTERDAM, April 23, 2024 /PRNewswire/ -- Flame Conference - The International Gas Union (IGU) releases its 2024 Global Wholesale Gas Price Survey report, the 16th undertaken since 2005.
  • Demand rebound in China and further growth in spot LNG imported into Europe contributed to the rise.
  • Global wholesale prices continued to significantly vary across regions, with Europe still remaining highest priced.
  • The maturing and growing flexibility of a truly global gas market are welcome signs from this year's survey results.

Roboquest releases 'Arsenal' update, enhancing gameplay with exciting new additions

Retrieved on: 
måndag, april 15, 2024
Moon, Element, Arsenal, Xbox, Summons, HUD, Shooting range, FPS, Artillery, Weapon, Rebecca Heineman, Steam, NPC, Third party, Shuriken, GOG, Video game

Boasting an Overwhelmingly Positive rating on Steam, Roboquest continues to enchant its growing fanbase with its intense gameplay and gripping action.

Key Points: 
  • Boasting an Overwhelmingly Positive rating on Steam, Roboquest continues to enchant its growing fanbase with its intense gameplay and gripping action.
  • The highly awaited Arsenal Update is out now, across multiple platforms including Steam, Xbox, Epic, and GOG.
  • The Arsenal Update introduces lots of new features, enhancing the gaming experience for both newcomers and seasoned players alike.
  • By rescuing Burger Bill, players gain access to the full potential of the Shooting Range, further expanding their gameplay experience.

Guild of Guardians Set to Revolutionize Mobile Gaming with Official Global Release on May 15

Retrieved on: 
torsdag, mars 21, 2024
Bandai Namco Holdings, SK Gaming, RPG, Team Liquid, Altar, Cloud9, Trailer, The Last of Us, NRG, Google Play, NFT, Golden Joystick Awards, Non-fungible token, App Store (iOS/iPadOS), Game, GOG, Polygon, Ecosystem, Final Fantasy, Dread, The Altar, Riot Games, AAA, Square Enix, Video game

SYDNEY, March 21, 2024 /PRNewswire/ -- Immutable Games today announced the official launch date of its flagship title, Guild of Guardians (GOG), a highly anticipated mobile squad-based RPG with over 1 million pre-registered users. Developed with the highly acclaimed studio, Mineloader, known for co-developing and working on some of the world's biggest AAA titles such as The Division 2, The Last of Us Part I, and the Final Fantasy series, GOG is set to make its global debut on May 15. Starting May 15, players worldwide can dive into the fantastical world of Elderym, building their ultimate team of Guardians to conquer the Dread. The game will be available on the Google Play and Apple App Store, following a highly successful soft launch in Canada, Australia and Indonesia where it gained an impressive 4.9 rating on the App Store.

Key Points: 
  • SYDNEY, March 21, 2024 /PRNewswire/ -- Immutable Games today announced the official launch date of its flagship title, Guild of Guardians (GOG), a highly anticipated mobile squad-based RPG with over 1 million pre-registered users.
  • Starting May 15, players worldwide can dive into the fantastical world of Elderym, building their ultimate team of Guardians to conquer the Dread.
  • With more than 1 million pre-registered users, and a passionate global community of over 400,000, Guild of Guardians is poised for global success.
  • Launching on mobile allows us to bridge the gap between traditional gaming and the emerging world of blockchain gaming," said Chris Clay, Game Director for Guild of Guardians.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Retrieved on: 
fredag, januari 12, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Histopathology, Weight loss, Gynaecology, Bevacizumab, Cisplatin, Hypothyroidism, University, Cancer, Risk, COVID-19, Diarrhea, Hyperthyroidism, Brachytherapy, Neoplasm, Perforated ulcer, Hepatitis, FIGO, CRT, Pyelonephritis, Colitis, Vagina, ClinicalTrials.gov, PD-L1, RECIST, Disease, Patient, Fever, CPS, Chemoradiotherapy, Vomiting, MRK, Death, Nephritis, Progression-free survival, OS, Radiation, Anemia, Survival, EBRT, Abdominal pain, Intraparenchymal hemorrhage, Uterus, Cervical cancer, Constipation, PFS, Fatal, Obstetrics, Hematopoietic stem cell transplantation, Pneumonitis, Nausea, Pelvic pain, Dysuria, Fatigue, GOG, Arm, Rash, Food, Merck & Co., Sepsis, Toxicity, News, Urinary tract infection, Appetite, Pharmaceutical industry

Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Key Points: 
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • “Building on the established role of KEYTRUDA in advanced cervical cancer, KEYTRUDA plus chemoradiotherapy is now the first anti-PD-1-based regimen approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer regardless of PD-L1 expression,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.
  • The trial enrolled 1,060 patients with cervical cancer who had not previously received any definitive surgery, radiation, or systemic therapy for cervical cancer.
  • In the exploratory subgroup analysis of 596 patients with FIGO 2014 Stage III-IVA disease, 61 patients (21%) in the KEYTRUDA plus CRT arm (n=293) experienced a PFS event versus 94 patients (31%) in the placebo plus CRT arm (n=303).

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Retrieved on: 
tisdag, november 14, 2023
Webcast, Interest, Gynecologic Oncology Group, Therapy, ASH, Rigosertib, Protein, Breast cancer, Patient, Mantle cell lymphoma, GOG, Research, FDA, Pharmacology, Neutropenia, SCC, Diarrhea, Ovarian cancer, Cancer, Development, Internet, Society, News, Face, Pharmaceutical industry, Birth control, Video game

NEWTOWN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results and provided an update on recent pipeline progress. Management plans to host a conference call and live webcast at 4:30 p.m. ET today to discuss these results.

Key Points: 
  • ET on Tuesday, November 14, 2023
    NEWTOWN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results and provided an update on recent pipeline progress.
  • “Onconova has made excellent progress in the third quarter of 2023.
  • Research and development expenses were $2.5 million for the third quarter of 2023, compared with $3.6 million for the second quarter of 2022.
  • General and administrative expenses were $2.7 million for the third quarter of 2023, compared with $2.1 million for the second quarter of 2022.

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Retrieved on: 
onsdag, december 13, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NDA, Paclitaxel, Woman, Institute of Cancer Research, Research, Safety, Food, Avutometinib, Cancer, Letrozole, Disease, Verastem Oncology, Patient, Anastrozole, GOG, PFS, Consultant, RAMP, Breakthrough therapy, Part, FDA, NHS foundation trust, FRAME, ORR, The Institute, Ovarian cancer, FRCP, Doctor of Philosophy, Physician, Accelerated approval (FDA), Royal Marsden Hospital, Pharmaceutical industry, MBBS, Topotecan

“Patients and treating physicians have advocated for more research and development in support of LGSOC.

Key Points: 
  • “Patients and treating physicians have advocated for more research and development in support of LGSOC.
  • At Verastem Oncology, we are moving with urgency to offer a Phase 3 study specifically directed at this disease in an effort to address this need,” said Dan Paterson, President and Chief Executive Officer, Verastem Oncology.
  • RAMP 301 is a global trial with enrollment open in the U.S. and planned enrollment in Canada, the United Kingdom, Europe, Australia, and Korea.
  • Dr. Grisham and Dr. Banerjee are paid consultants for Verastem Oncology.

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
onsdag, november 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Standard of care, NSCLC, Food, Pancreas, Anastrozole, Regulatory affairs, Ovarian cancer, GAAP, Pancreatic Cancer Action Network, Paclitaxel, Accelerated approval (FDA), ORR, European Network of Transmission System Operators for Electricity, Safety, Cancer, Therapy, Investment, Patient, General Administration of Sport of China, Verastem Oncology, Topotecan, Conference, Bank statement, Clinical trial, FRAME, Travel, Letrozole, RAMP, FDA, SOC, AACR, RAS, Research and development, The Annual Global Orgasm for Peace, GOG, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, KRAS, Senior, Pharmacokinetics, European Society of Gynaecological Oncology, Lung cancer, Table, Diagnosis, Pharmaceutical industry, Bank, Finance

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.
  • Verastem Oncology ended the third quarter of 2023 with cash, cash equivalents and investments of $165.7 million.
  • Research & development expenses for the 2023 Quarter were $13.9 million, compared to $11.3 million for the 2022 Quarter.
  • Selling, general & administrative expenses for the 2023 Quarter were $7.4 million, compared to $6.4 million for the 2022 Quarter.